Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

Moments after Regeneron CEO Len Schleifer scolded analysts for asking too many questions about the disappointing sales of eye ...

It's been cleared for second-line use in patients who have progressed or are intolerant to hedgehog inhibitor therapy. Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out ...

Sanofi said the results are strong enough to support a new indication in the US and EU for Libtayo, a PD-1 inhibitor that is already FDA-approved in advanced cutaneous squamous cell carcinoma.

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

The potential use of Libtayo described above is investigational, and its safety and efficacy has not been evaluated by any regulatory authority for this indication. C-POST is an ongoing randomized, ...

Immuneering plans to evaluate IMM-1-104 in combination with Libtayo in patients with advanced non-small cell lung cancer in its ongoing Phase ...

Adults with a type of lung cancer called non-small cell lung cancer (NSCLC). LIBTAYO may be used in combination with chemotherapy that contains a platinum medicine as your first treatment when ...

The supply agreement supports the evaluation of Immuneering’s lead product candidate, IMM-1-104, in combination with Libtayo in patients with unresectable or metastatic RAS-mutant non-small cell ...